New Report Available: Chile Pharmaceuticals & Healthcare Report Q3 2013
The lack of vigilance in bioequivalence regulations in Chile has allowed for the proliferation of low quality medicines in the market. These can risk patients' lives and negatively affect the local pharmaceutical industry's global competitiveness. Despite the ongoing capacity issues reported by domestic manufacturers, we believe generic drugmakers in Chile need to adopt necessary production processes to guarantee their drug quality.
View full press release